Dual endothelin receptor antagonist — successor to bosentan with sustained tissue binding and once-daily dosing. PAH; hepatotoxicity is less than bosentan. Anemia + nasopharyngitis are the more common adverse effects.
Half-Life & Elimination Curve (PO: 16h)
Plasma (PO)t½ Decay (16h)
0×t½0h100%(78.1 µg/L)
1×t½16h50%(39 µg/L)
2×t½32h25%(19.5 µg/L)
3×t½48h12.5%(9.76 µg/L)
4×t½64h6.3%(4.88 µg/L)
5×t½3.3d3.1%(2.44 µg/L)
Elimination t½16h (PO)
Rate Constant (ke)0.0433 h⁻¹
Time to Peak (Tmax)14.8h
Est. Peak (Cmax)78.1 µg/L
Clearance (CL)2.17 L/h
97% Washout (5×t½)3.3d
Dosing Guidelines
Oral (PO): Typical 10 mg
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 74% · Volume of Distribution (Vd): 50 L · Absorption (ka): 0.1 h⁻¹ (t½ka ≈ 6.93h) [PMID 23900878]